Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer

References

• Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17–I21.
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJM, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–722.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624.
   PubMed Web of Science ®Google Scholar
• Win KZ, Wilson N, Stenehjem DD, et al. Effectiveness and safety of rivaroxaban in treatment of venous thromboembolism in cancer patients. Blood. 2015;126(23):2319–2319.
   Web of Science ®Google Scholar
• Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891–1894.
   PubMed Web of Science ®Google Scholar
• McBane RD, 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–421.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Keshishian A, Lee T, et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a US claims data analysis. Thromb Hemost. 2021;121(3):383–395.
   PubMed Web of Science ®Google Scholar
• Streiff MB, Holmstrom B, Angelini D, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 1. 2020. [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; c1993. 2020. [cited 2020 Aug 17]; [133 screens]. Available from: http://medi-guide.meditool.cn/ymtpdf/9E219C23-6627-2971-9CC9-2BB8D86873AA.pdf.
   Google Scholar
• Farge D, Frere C, Connors JM, et al. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–e581.
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648–655.
   PubMed Web of Science ®Google Scholar
• Martín-Martos F, Trujillo-Santos J, Del Toro J, et al. Gender differences in patients with venous thromboembolism and five common sites of cancer. Thromb Res. 2017;151(Suppl 1):S16–S20.
   PubMed Web of Science ®Google Scholar
• Khorana AA, McCrae KR. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res. 2014;133(Supply 2):S35–S38.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607.
   PubMed Web of Science ®Google Scholar
• Teutsch C, Huisman MV, Lip GYH, et al. Persistence with dabigatran therapy for stroke prevention in patients with non-valvular atrial fibrillation: the Gloria-AF Registry. Blood. 2016;128(22):2616–2616.
   PubMed Web of Science ®Google Scholar
• Chee CE, Ashrani AA, Marks RS, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood, J Am Soc Hematol. 2014;123(25):3972–3978.
   Google Scholar
• Trujillo-Santos J, Ruiz-Gamietea A, Luque JM, et al. RIETE Investigators. Predicting recurrences or major bleeding in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res. 2009;123(Suppl 2):S10–S15.
   PubMed Web of Science ®Google Scholar
• Louzada ML, Majeed H, Dao V, et al. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis. 2011;22(2):86–91.
   PubMed Web of Science ®Google Scholar
• Insin P, Vitoopinyoparb K, Thadanipon K, et al. Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery: a systematic review and network meta-analysis. Gynecol Oncol. 2021;161(1):304–313.
   PubMed Web of Science ®Google Scholar
• Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35(30):5642–5655.
   PubMed Web of Science ®Google Scholar
• NCI Comorbidity Index Overview [Internet]. Bethesda (MD): National Cancer Institute; c1937. 2019. May 23 [cited 2020 Aug 17]; [about 6 screens]. https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html.
   Google Scholar
• Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839–4847.
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler C, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–5382.
   PubMed Web of Science ®Google Scholar
• Ross JA, Miller MM, Hernandez CMR. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res. 2017;150:86–89.
   PubMed Web of Science ®Google Scholar
• Wysokinski WE, Houghton DE, Casanegra AI, et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol. 2019;94(11):1185–1192.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023.
   PubMed Web of Science ®Google Scholar
• Dawwas GK, Dietrich E, Smith SM, et al. Comparative effectiveness and safety of direct-acting oral anticoagulants and warfarin in patients with venous thromboembolism and active cancer: an observational analysis. Clin Ther. 2020;S0149-2918(20):30332–30335.
   Google Scholar
• Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost. 2018;118(8):1439–1449.
   PubMed Web of Science ®Google Scholar
• Moik F, Posch F, Zielinski C, et al. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost. 2020;4(4):550–561.
   PubMed Web of Science ®Google Scholar
• Ageno W, Vedovati MC, Cohen A, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost. 2021;121(5):616–624.
   PubMed Web of Science ®Google Scholar
• Broder MS, Neary MP, Chang E, et al. Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary. 2014;17(4):333–341.
   PubMed Web of Science ®Google Scholar